Clin2
NCT07337564Possibly a fitNot yet recruiting

Study of SHR-1139 for ulcerative pyoderma gangrenosum

Pyoderma Gangrenosum

Part of Skin clinical trials.

This study tests an investigational drug called SHR-1139 for adult patients with ulcerative pyoderma gangrenosum (a type of painful skin ulcer). The goal is to see if the drug is safe and helps heal the ulcers.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been diagnosed with ulcerative pyoderma gangrenosum (a painful skin ulcer condition) that needs treatment with a systemic medication (like pills or shots)
  • You have at least one PG ulcer a doctor can measure right now
  • You agree to use effective birth control (if you or your partner could become pregnant) from now until 72 weeks after last dose
  • You are not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07444684Not yet recruiting· Phase 2
Studying SHR-1139 for pyoderma gangrenosum ulcers

This trial tests an injection called SHR-1139 for people with pyoderma gangrenosum (a rare skin condition that causes painful ulcers). If you have at least one ulcer that is 5 cm² or larger and your PARACELSUS score is at least 10, you may be able to join.

Jinan, Shandong
NCT06563323Recruiting· Phase 2
Testing Guselkumab for Pyoderma Gangrenosum

This study tests whether guselkumab (Tremfya) can help heal painful ulcers from Pyoderma Gangrenosum (PG). Participants must already be taking steroid medication and have a PG ulcer that is at least 4 cm².

Columbus, Ohio
NCT06624670Recruiting· Phase 3
Testing spesolimab for pyoderma gangrenosum skin ulcers

This trial tests whether the drug spesolimab can help people with a skin condition called pyoderma gangrenosum, which causes painful ulcers. It's for adults who have at least one active ulcer that's at least 2 inches across and needs treatment.

Birmingham, Alabama
NCT07767864Not yet recruiting· Phase 2
Bimekizumab for pyoderma gangrenosum ulcers

This study tests whether the drug bimekizumab can help heal ulcers caused by a rare skin condition called pyoderma gangrenosum (PG). If you have PG and are already taking prednisone, this trial may offer a new treatment option.

Portland, Oregon
NCT07783412Not yet recruiting· Phase 2
Ruxolitinib cream for pyoderma gangrenosum ulcers

This study tests a cream called ruxolitinib for people with pyoderma gangrenosum, a condition that causes painful skin ulcers. The cream is applied directly to the ulcer, and the study aims to see if it helps heal the wounds.

NCT07758075Not yet recruiting· Phase 2
A new treatment for plaque psoriasis

This study tests an experimental drug, SHR-1139, given as an injection, to see if it can help people with plaque psoriasis who haven't gotten enough relief from other biologic treatments. It aims to improve skin symptoms and quality of life.

Changsha, Hunan

Hear when a new Pyoderma Gangrenosum trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.